Clinical trials: Anti Vascular Endothelial Growth Factor
Ophthalmology, Macular Degeneration
Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA)
Retrospective, non-interventional, observational multi-center field study. Patients diagnosed with wet Age-related macular degeneration (wAMD) and having started treatment with ranibizumab between January 1, 2009 and August 31…
- Trial name
- AURA (NCT01447043)
- Testing
- Ranibizumab
- Where
- 10 sites in Australia, Canada and 8 more
- Volunteers
- 2,609 people
- Sponsor
- Bayer
Diabetic Macular Edema
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with treatment-naïve DME.
- Trial name
- GLEAM (NCT04611152)
- Testing
- KSI-301, Aflibercept
- Where
- 75 sites in United States, Germany and 6 more
- Volunteers
- 460 people
- Sponsor
- Kodiak Sciences Inc
Retinal Vein Occlusion
Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy
The purpose of this study is determine the number of patients with complete resolution of macular edema secondary to central retinal vein occlusion following 6 monthly injections of Aflibercept.
- Trial name
- NCT01857544
- Testing
- Aflibercept
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Tennessee Retina
Diabetic Macular Edema
Treatment for CI-DME in Eyes With Very Good VA Study
Although multiple studies have clearly demonstrated that ranibizumab therapy is more effective than laser alone for vision gain and avoiding vision loss in patients with central-involved Diabetic Macular Edema (DME), only eyes…
- Trial name
- Protocol V (NCT01909791)
- Testing
- Prompt Laser, Prompt aflibercept, Deferred laser
- Where
- 103 sites in United States, Canada
- Volunteers
- 702 people
- Sponsor
- Jaeb Center for Health Research
Hepatocellular Carcinoma (HCC)
Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without HAIC for Unresectable HCC With Portal Vein Tumor Thrombosis
Anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors (VEGF/TKI-ICI) plus Immune checkpoint inhibitors (ICIs) are recommended for patients with unresectable hepatocellular carcinoma (HCC) with PVTT in China.
- Trial name
- NCT06881433
- Where
- China
- Volunteers
- 1,649 people
- Sponsor
- Zhongda Hospital
Malignant Melanoma
A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma
This study will assess the preliminary anti-tumor activity and safety profile of a combination of bevacizumab and dacarbazine in participants with unresectable/metastatic melanoma not previously treated with chemotherapy for…
- Trial name
- NCT01164007
- Testing
- Bevacizumab, Dacarbazine
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Hoffmann-La Roche
AKI Incidence of Cancer Patients Receiving AntiVEGF or ICIs
Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular Endothelial Growth Factor Monoclonal Antibody vs Immune Checkpoint Inhibitors
The goal of this a retrospective real-world study is to compare the AKI events in cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody (AntiVEGF) vs immune checkpoint inhibitors (ICIs).
- Trial name
- NCT06119347
- Testing
- AntiVEGF, ICIs
- Where
- China
- Volunteers
- 1,581 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Proliferative Diabetic Retinopathy, Vascular Endothelial Growth Factor Overexpression
Macular Perfusion Changes After Anti-VEGF Versus Targeted Retinal Photocoagulation in Proliferative Diabetic Retinopathy
Diabetic retinopathy (DR) is the most common microvascular complication of diabetes mellitus (DM), while proliferative diabetic retinopathy (PDR) is the principal cause of severe visual loss in patients with diabetes.
- Conditions
- Proliferative Diabetic Retinopathy, Vascular Endothelial Growth Factor Overexpression, Diabetic Retinopathy
- Trial name
- PROPER (NCT04674254)
- Testing
- Bevacizumab Injection, Targeted retinal photocoagulation, Standard pan-retinal photocoagulation
- Where
- Egypt
- Volunteers
- 43 people
- Sponsor
- Cairo University
Cancer
Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy
We are conducting a research study for tumors that have not responded to prior treatment. The subject will receive an investigational drug called IMC-1121B. ImClone LLC, the maker of IMC-1121B, is running this research study.
- Trial name
- NCT00786383
- Testing
- IMC-1121B, 1121B
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Eli Lilly and Company
Diabetic Retinopathy, Diabetic Macular Edema
Anti-VEGF Treatment for Prevention of PDR/DME
Multiple studies have implicated vascular endothelial growth factor VEGF as a major causative factor in human eye diseases characterized by neovascularization including proliferative diabetic retinopathy (PDR) and vascular…
- Trial name
- NCT02634333
- Testing
- Prompt aflibercept, Deferred laser, Deferred aflibercept
- Where
- 85 sites in United States, Canada
- Volunteers
- 399 people
- Sponsor
- Jaeb Center for Health Research
Renal Function Disorder, Diabetic Macular Edema (DME)
Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients
This study aims to investigate the impact of intravitreal injection of anti-vascular endothelial growth factor (anti VEGF) Faricimab on renal function of diabetic patients.
- Conditions
- Renal Function Disorder, Diabetic Macular Edema (DME), Neovascular Age Related Macular Degeneration
- Trial name
- NCT06929507
- Testing
- Intravitreal injection of Faricimab or Aflibercept 2 mg
- Where
- 2 sites in Greece
- Volunteers
- 60 people
- Sponsor
- University Hospital, Alexandroupolis
Neovascular Age-related Macular Degeneration, Macular Degeneration
Photodynamic Therapy for PDA in NV AMD
The purpose of this prospective observational study is to assess the potential clinical effects of adjunctive verteporfin photodynamic therapy (PDT) for persistent disease activity among patients with neovascular age-related…
- Trial name
- NCT02452840
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Duke University
Tumors, Neoplasm Metastasis
Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer
The objective of this study is to assess the safety, tolerability, dose limiting toxicity, and maximum tolerated dose of vatalanib administered orally once daily in combination with capecitabine in patients with advanced cancer.
- Trial name
- NCT00171587
- Testing
- PTK787/ZK 222584 (vatalanib)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Novartis
Retinal Pigment Epithelial Detachment
Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments
This is a multicenter, randomized, open-label study. 40 patients will be followed for a period of 12 months. All consented and enrolled patients will receive either 0.5mg or 2.0mg of intravitreal ranibizumab injection.
- Trial name
- NCT00749021
- Testing
- Ranibizumab
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Clement K. Chan
Macular Disease
Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics
The objective of this research is to determine the effects of anti-VEGF drugs (bevacizumab, ranibizumab or aflibercept) on aqueous humor dynamics (AHD) in patients with retinal vascular disease.
- Trial name
- NCT01994174
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- University of Nebraska
Macular Degeneration, Regional Blood Flow
The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion
Age related macula degeneration is one of the most common sight threatening diseases of the elderly. The so called wet form of AMD is caused by choroidal neovascularisation (CNV) of pathological vessels, which lead to leakage…
- Conditions
- Macular Degeneration, Regional Blood Flow, Vascular Endothelial Growth Factor
- Trial name
- NCT00709657
- Testing
- ranibizumab, bevacizumab or pegaptanib
- Where
- Austria
- Volunteers
- 8 people
- Sponsor
- Medical University of Vienna
Macular Edema
A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease
AURIGA is designed to collect data from routine clinical practice on the effectiveness and utilization of intravitreal aflibercept in the treatment of visual impairment due to diabetic macular edema (DME) or macula edema…
- Trial name
- AURIGA (NCT03161912)
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- 11 sites in China, Egypt and 9 more
- Volunteers
- 2,481 people
- Sponsor
- Bayer
Diabetic Macular Edema
Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema
To determine if there is visual benefit with Ozurdex treatment every three months compared to monthly anti-VEGF alone, in subjects with persistent diabetic macular edema.
- Trial name
- NCT02036424
- Testing
- Ozurdex, Bevacizumab
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Raj K. Maturi, MD
Eye Diseases, Injection Complication
Brinzolamide-brimonidine Fixed Combination for Preventing IOP Elevation After Intravitreal Anti-VEGF Injections
This study aims to evaluate the effect of topical prophylaxis with brinzolamide-brimonidine fixed combination on short-term intraocular pressure (IOP) elevation after intravitreal injections of anti-vascular endothelial growth…
- Conditions
- Eye Diseases, Injection Complication, Intraocular Pressure
- Trial name
- NCT04523844
- Testing
- Brinzolamide-brimonidine Fixed Combination
- Where
- Greece
- Volunteers
- 47 people
- Sponsor
- General Hospital of Athens Elpis
Advanced Solid Tumor
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or…
- Trial name
- NCT07070232
- Testing
- BNT326, Pumitamig, Itraconazole
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 1,438 people
- Sponsor
- BioNTech SE